logo-loader
viewPhosplatin Therapeutics

Phosplatin Therapeutics 'excited' about its prostate cancer data presentation next week

Phosplatin Therapeutics CEO Robert Fallon sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York. The New York-based, clinical stage oncology drug development company announced today it will present clinical data in metastatic castration resistant prostate cancer at the Genitourinary Cancers Symposium.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

14 hours, 43 minutes ago

2 min read